Verastem/VSTM

$9.84

-1.75%
-
1D1W1MYTD1YMAX

About Verastem

Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).

Ticker

VSTM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel Paterson

Employees

73

Headquarters

Cambridge, United States

Verastem Metrics

BasicAdvanced
$249.03M
Market cap
-
P/E ratio
-$4.07
EPS
0.59
Beta
-
Dividend rate
$249.03M
0.59189
$15.18
$4.26
146.22K
5.447
51.044
51.044
-71.39%
-166.79%
-88.82%
4.336
3.171
-100%
11.28%

What the Analysts think about Verastem

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
192.58% upside
High $36.00
Low $17.50
$9.84
Current price
$28.79
Average price target

Verastem Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-27.3M
36.5%
Profit margin
0%
-

Verastem Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 64.52%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.96
-$1.37
-$0.75
-$1.02
-
Expected
-$0.98
-$1.06
-$0.84
-$0.62
-$1.03
Surprise
-2.44%
29.25%
-11.02%
64.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Verastem stock?

Verastem (VSTM) has a market cap of $249.03M as of April 22, 2024.

What is the P/E ratio for Verastem stock?

The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of April 22, 2024.

Does Verastem stock pay dividends?

No, Verastem (VSTM) stock does not pay dividends to its shareholders as of April 22, 2024.

When is the next Verastem dividend payment date?

Verastem (VSTM) stock does not pay dividends to its shareholders.

What is the beta indicator for Verastem?

Verastem (VSTM) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Verastem stock price target?

The target price for Verastem (VSTM) stock is $28.79, which is 192.58% above the current price of $9.84. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Verastem stock

Buy or sell Verastem stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing